{"groups":[{"description":"Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib, 960 milligrams (mg) twice daily, in 28-day cycles, for up to 52 weeks","id":"FG000","title":"Cohort 1 Vemurafenib"},{"description":"Participants with completely resected Stage IIC, IIIA, or IIIB cutaneous melanoma) received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks","id":"FG001","title":"Cohort 1 Placebo"},{"description":"Participants with Stage IIIC cutaneous melanoma received vemurafenib, 960 mg twice daily, in 28-day cycles, for up to 52 weeks","id":"FG002","title":"Cohort 2 Vemurafenib"},{"description":"Participants with Stage IIIC cutaneous melanoma received vemurafenib-matching placebo twice daily, in 28-day cycles, for up to 52 weeks","id":"FG003","title":"Cohort 2 Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Reason Not Specified"},{"reasons":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"9"},{"groupId":"FG003","numSubjects":"8"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"}],"type":"Non-compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"4"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"33"},{"groupId":"FG002","numSubjects":"25"},{"groupId":"FG003","numSubjects":"26"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"157"},{"groupId":"FG001","numSubjects":"157"},{"groupId":"FG002","numSubjects":"93"},{"groupId":"FG003","numSubjects":"91"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"114"},{"groupId":"FG001","numSubjects":"110"},{"groupId":"FG002","numSubjects":"57"},{"groupId":"FG003","numSubjects":"52"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"43"},{"groupId":"FG001","numSubjects":"47"},{"groupId":"FG002","numSubjects":"36"},{"groupId":"FG003","numSubjects":"39"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}